According to the US Food and Drug Administration’s clinical trial, a single 6 mL injection of Synvisc One has provided symptomatic relief for up to 26 weeks in patients with knee osteoarthritis (OA). This study underscores Synvisc-One’s therapeutic potential and emphasizes its safety and effectiveness following its approved indications.
Medical professionals often turn to viscosupplementation when first-line therapies fall short, specifically Synvisc One. Fortunately, Synvisc One’s dosage and frequency stand out from other viscosupplement brands. Its unique single-injection therapy offers a cost-effective and convenient treatment that can provide relief for up to six months.
This article will delve into Synvisc dosage, repeat dosing regimens, and its proper administration for patients suffering from knee OA.
Key Takeaways
- A proper Synvisc dosage can help patients achieve their goals and specific knee osteoarthritis conditions.
- The initial dosage for Synvisc One involves injecting the entire 6 mL syringe contents into one knee only.
- Medical professionals can recommend Synvisc One for repeat treatments, allowing patients to maintain pain-free movement and improved quality of life.
- Proper administration techniques can help deliver the medicine efficiently into the affected knee joint.
- Learning about the injecting process, benefits, potential risks, and post-treatment care can increase patient satisfaction.
- A thorough consultation is necessary to align and maximize the treatment’s benefits to the patient’s knee osteoarthritis (OA) condition and health.
About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. If you’re looking to order Synvisc online, you can do so on Medica Depot quickly and easily. We offer a worry-free experience in searching for the best and most popular products on the market. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.
Dosing Regimens for Synvisc One
Synvisc One offers a single injection therapy for individuals suffering from early to severe knee osteoarthritis (OA). Each Synvisc dosage requires an intra-articular injection directly into the affected knee joint, administered by a healthcare provider, to ensure safe treatment.
Administering a proper Synvisc dosage can help patients achieve their desired goals and specific knee OA conditions. Medical professionals can maximize Synvisc One’s benefits while reducing the potential risks without compromising the patient’s health.
Initial Dosing
The initial dosage for Synvisc One involves injecting the entire 6 mL syringe contents into one knee only. Each affected joint requires a separate syringe and should receive 6 mL per knee. Medical professionals must administer this single injection directly into the affected knee joint.
Healthcare providers should consider several factors when determining the initial Synvisc dosage for each patient. It’s worth noting that Synovsic One has contraindications, which can ensure that patients receive a safe and effective injection treatment and minimize Synvisc side effects.
- Do not administer to patients with known hypersensitivity (allergy) to hyaluronan (sodium hyaluronate) preparations.
- Do not inject Synvisc One in the knees of patients having knee joint infections, skin diseases, or infections in the area of the injection site.
Besides Synvisc One’s contraindications, factors that may affect the initial dosage may include the patient’s overall health, knee OA condition, current medications, treatment response, and their specific goals to achieve after the treatment.
Repeat Dosing
Medical professionals can recommend Synvisc One for repeat treatments, allowing patients to maintain pain-free movement and improved quality of life. In its Frequently Asked Questions about repeat injections, Synvisc One mentioned a medical study in which 160 patients, 77, safely received a second injection of Synvisc One.
Providers administer a single 6 mL Synvisc One injection per cycle in this injection treatment. In contrast, the original Synvisc requires three separate injections at weekly intervals. Interestingly, Synvisc treatment cycles can be repeated as needed, usually around six (6) months after a complete cycle.
Administration Techniques
Medical professionals play a crucial role in the Synvisc One treatment process. Proper administration techniques can help deliver the medicine efficiently into the affected knee joint. In Synvisc One’s treatments, providers must utilize a strict aseptic injection technique.
Injection Site
The US Food and Drug Administration has indicated and approved Synvisc One solely for the knees. Furthermore, the recommended injection site is directly into the knee joint. Providers should administer this injection to ensure the entire syringe content reaches the affected joint.
Providers must remove any synovial fluid or effusion before injecting the solution into the site and administer single-injection therapy. Synvisc One should be used cautiously in specific patient populations, such as patients allergic to avian proteins, feathers, or egg products.
Additionally, the Synvisc One manufacturer has yet to establish the safety and effectiveness of the solution for pregnant women, breastfeeding women, and children below 21. Other specific populations that may require a more patient-centric approach are as follows:
- Elderly Patients: Older individuals can benefit from Synvisc One therapy but may need adjustments due to age-related changes in drug metabolism.
- Athletes: Synvisc One can provide significant and lasting pain relief to athlete patients. However, it’s necessary to rest the knee after the injection before returning to their active lifestyle. Moreover, combining Synvisc One with regular exercise can help maintain the effects.
Injection Procedure
Medical professionals must ensure that patients understand the entire Synvisc One injection treatment and inform them of the steps that occur during the procedure. Learning about the injecting process, benefits, potential risks, and post-treatment care can increase patient satisfaction.
- Cleaning or Disinfecting: Medical professionals must properly disinfect the site after marking the location for the Synvisc One injection.
- Local Anesthesia: Numbing the skin with a local anesthetic before the intra-articular injection can help patients feel more comfortable during the injection process.
- Injection Process: Providers must remove joint effusion in the injection site before injecting. Afterward, they must use an 18- to 20-gauge needle to administer Synvisc One and inject a total of 6 mL in one knee only.
Medical professionals may suggest various post-injection treatment care for patients. Ice application can help in minimizing pain and swelling at the injection site. To ensure proper administration, healthcare providers may need to remember several tips.
- Do not inject Synvisc One extra-articularly into the synovial tissues, fat pad, joint capsule, or intravascularly.
- Avoid disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence.
- They should advise patients to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment.
Patient-Specific Considerations
Medical professionals should consider specific patient considerations before injecting Synvisc One into patients. A thorough consultation is necessary to align and maximize the treatment’s benefits to the patient’s knee osteoarthritis (OA) condition and health.
Age and Weight
Aside from the mentioned contraindications and cautions, age and weight can also affect the Synvisc dosage for each patient. According to Synvisc One, only individuals aged 22 and higher can receive the single-injection treatment, which may effectively work better and longer for patients with milder cases of knee osteoarthritis (OA).
However, the Synvisc manufacturer has not explicitly mentioned the impact of weight and age on Synvisc dosage. While there’s no specific guidance on adjusting Synvisc One based on these factors, medical professionals can alter the dose depending on the patient’s needs.
Along with age and weight, they should consider the patient’s overall health status, existing medical conditions, and other medications they may be taking. Medical professionals know best about adjusting dosage, and they can effectively help patients align Synvisc One treatment with their condition and goals.
Conclusion
Synvisc One is a unique treatment for knee osteoarthritis (OA) symptoms. Its cost-effective dosing regimen stands out from other options. It only requires a single injection, making it a convenient choice for many patients. Manufacturers have crafted the Synvisc dosage to provide optimal symptomatic relief from knee OA.
The administration of Synvisc One involves a specific technique that healthcare providers must adhere to to ensure a safe and effective treatment outcome. Providers can depend on patient-specific considerations to create a personalized treatment plan and ensure Synvisc’s efficacy in managing knee OA.
FAQs
1. What is Synvisc One used for?
Synvisc One is a type of injection used for treating knee pain caused by osteoarthritis. It is a gel-like substance injected directly into the knee joint, which helps to lubricate and cushion the joint, reducing pain and improving mobility.
2. How is Synvisc One administered?
Synvisc One is administered as a single injection directly into the knee joint by a healthcare professional. The procedure usually takes several minutes in a doctor’s office or clinic. After the injection, the patient may be advised to rest briefly before resuming normal activities.
3. What is the recommended dosage for Synvisc One?
The recommended dosage for Synvisc One is a single injection of 6 mL, administered directly into the knee joint. This is considered an entire course of treatment, and most patients will not require additional injections.
References
- SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED). (n.d.). In accessdata.fda.gov. Retrieved April 26, 2024, from https://www.accessdata.fda.gov/cdrh_docs/pdf/P940015S012B.pdf
- Llamas, M. (2023). Synvisc-One Knee Injections | Uses, Studies and Recalls (E. Miller, Ed.). Drugwatch.com. https://www.drugwatch.com/synvisc-one/
